Camilla Petrycer Hansen

Camilla Hansen joined the Novo Holdings Seed Investments team in June 2018.

In January 2025, Camilla took over the leadership of the REPAIR Impact Fund while continuing to drive company creation and maturation under the Novo Holdings Seed Investments strategy.

Prior to joining Novo Holdings A/S, Camilla spent 10 years in business development in early academic start-ups, maturing biotechs and industry.

Camilla serves as director on the boards of Muna therapeutics, LimmaTech Biologics, Hoba Therapeutics, Precirix, Centauri Therapeutics, AMR Action Fund and is a board observer on Paratek.

Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.